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BACKGROUND
The combined inhibition of BRAF and MEK is hypothesized to improve clinical 
outcomes in patients with melanoma by preventing or delaying the onset of resis-
tance observed with BRAF inhibitors alone. This randomized phase 3 study evalu-
ated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor 
cobimetinib.
METHODS
We randomly assigned 495 patients with previously untreated unresectable locally 
advanced or metastatic BRAF V600 mutation–positive melanoma to receive vemu-
rafenib and cobimetinib (combination group) or vemurafenib and placebo (control 
group). The primary end point was investigator-assessed progression-free survival.
RESULTS
The median progression-free survival was 9.9 months in the combination group 
and 6.2 months in the control group (hazard ratio for death or disease progression, 
0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or 
partial response in the combination group was 68%, as compared with 45% in the 
control group (P<0.001), including rates of complete response of 10% in the com-
bination group and 4% in the control group. Progression-free survival as assessed 
by independent review was similar to investigator-assessed progression-free sur-
vival. Interim analyses of overall survival showed 9-month survival rates of 81% 
(95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the 
control group. Vemurafenib and cobimetinib was associated with a nonsignifi-
cantly higher incidence of adverse events of grade 3 or higher, as compared with 
vemurafenib and placebo (65% vs. 59%), and there was no significant difference in 
the rate of study-drug discontinuation. The number of secondary cutaneous cancers 
decreased with the combination therapy.
CONCLUSIONS
The addition of cobimetinib to vemurafenib was associated with a significant im-
provement in progression-free survival among patients with BRAF V600–mutated 
metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann–
La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.)
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A pproximately 50% of metastatic cu-taneous melanomas harbor a BRAF V600 mutation, resulting in constitutive activa-
tion of the mitogen-activated protein kinase 
(MAPK) pathway.1,2 These discoveries led to the 
development of agents that specifically target this 
driver mutation. The BRAF inhibitor vemurafenib 
(Zelboraf, Genentech) was approved worldwide 
on the basis of results from a phase 3 trial show-
ing improved progression-free survival and over-
all survival, as compared with chemotherapy 
alone; the relative reduction in the risk of death 
was 63% and in the risk of disease progression 
was 74%.3 Similar results were also reported for 
another BRAF inhibitor, dabrafenib,4 which has 
also been approved widely. Although common 
toxic events with both agents are similar (rash, 
fatigue, and joint pain), the incidence of clini-
cally significant photosensitivity is higher with 
vemurafenib, whereas the incidence of clinically 
significant pyrexia is higher with dabrafenib. A 
toxic event common to both is secondary cutane-
ous squamous-cell carcinomas and keratoacan-
thomas, which occur in approximately 14 to 26% 
of patients treated with a BRAF inhibitor, usually 
within the first 2 to 3 months of therapy.5,6 The 
skin tumors develop owing to a paradoxical acti-
vation of the MAPK pathway in keratinocytes 
with upstream activation of signaling by preex-
isting RAS mutations,7,8 which can be blocked 
with the addition of a MEK inhibitor.8
Progression after a period of tumor response 
(acquired resistance) is common with single-agent 
BRAF-inhibitor therapy after a median progres-
sion-free survival of 6 to 7 months.3,4 The mecha-
nisms of acquired resistance are diverse and in-
clude the reactivation of oncogenic signaling by 
means of the MAPK pathway in approximately 
two thirds of cases and mechanisms that lead to 
MAPK pathway–independent signaling that sub-
stitutes for the inhibited driver oncogenic signal 
within the MAPK pathway.9-11 The finding of mul-
tiple genetic mechanisms of escape in individual 
patients10 implies that upfront inhibition of both 
MEK and the mutant BRAF kinases might be a 
strategy for obtaining more durable responses 
than the inhibition of BRAF alone.
Preclinical and clinical data suggest that the 
inhibition of both MEK and mutant BRAF kinases 
might result in a greater initial tumor response, 
prevent MAPK-driven acquired resistance, and de-
crease the frequency and severity of toxic events 
that occur owing to paradoxical MAPK-pathway 
activation from BRAF-inhibitor monotherapy. Tra-
metinib, a MEK inhibitor, was approved for the 
treatment of BRAF-mutated metastatic melanoma 
as a single agent after an improvement in pro-
gression-free and overall survival was shown in a 
randomized trial12 and in combination with 
dabrafenib on the basis of improvement in pro-
gression-free survival.13 Cobimetinib (also known 
as GDC-0973 [Roche] or XL518 [Exelixis]) is an 
orally bioavailable, potent, and selective MEK in-
hibitor.14 The most common toxic events associat-
ed with single-agent use of cobimetinib in phase 1 
testing were diarrhea, rash, fatigue, and edema; 
grade 3 or higher events included diarrhea, rash, 
and fatigue.
Cobimetinib in combination with vemurafenib 
was studied in patients with advanced BRAF 
V600–mutated melanoma in a phase 1b study 
(BRAF Inhibitor in Melanoma [BRIM] 7).15 Dose 
escalation was stopped at the maximum tolerated 
single-agent dose of each drug, with daily dosing 
of vemurafenib and cobimetinib administered for 
21 days, followed by 7 days off. At these doses, 
a confirmed objective response was noted in 55 
of 63 patients (87%) who had never received a 
BRAF inhibitor, and the antitumor activity ap-
peared to be favorable, as compared with his-
torical single-agent vemurafenib activity.3 Com-
mon adverse events were similar to those observed 
with the single agents and included rash, diar-
rhea, photosensitivity, and hepatic-enzyme ab-
normalities, and as expected, the incidence of 
cutaneous secondary cancers was decreased. To 
confirm and build on these early data, we report 
on the primary end point of coBRIM, an inter-
national, multicenter, randomized phase 3 study 
that evaluated the efficacy and safety of cobi-
metinib combined with vemurafenib in previously 
untreated patients with advanced BRAF-mutated 
melanoma.
ME THODS
PATIENTS
Eligible patients were at least 18 years of age; had 
histologically confirmed unresectable, locally 
advanced stage IIIC or stage IV melanoma with a 
BRAF V600 mutation detected with the use of a 
real-time polymerase-chain-reaction assay (Cobas 
4800 BRAF V600 Mutation Test, Roche Molecular 
Systems); had measurable disease, according to 
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the Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1,16 as assessed by means of 
computed tomography; had an Eastern Coopera-
tive Oncology Group (ECOG) performance-status 
score of 0 (fully active and able to carry on all 
performance without restriction) or 1 (restricted 
in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary 
nature); and had adequate hematologic, hepatic, 
renal, and cardiac function. Patients with previ-
ously treated brain metastases were eligible if they 
had at least a 3-week history of stable disease. 
STUDY OVERSIGHT
The study was approved by the institutional re-
view board or ethics committee at each partici-
pating institution and was conducted in accordance 
with the provisions of the Declaration of Helsin-
ki and the International Conference on Harmon-
isation guidelines for Good Clinical Practice. All 
the patients provided written informed consent. 
An independent data and safety monitoring com-
mittee conducted regular review and evaluation 
of the safety data.
F. Hoffmann–La Roche/Genentech sponsored 
the study. All the authors and their research teams 
collected the data. Representatives of the spon-
sor and the members of the study steering com-
mittee designed the study. Representatives of the 
sponsor confirmed the accuracy of the data and 
compiled the data for analysis. The analysis was 
performed in collaboration with the authors. All 
the authors had full access to the data and analy-
ses pertinent for the compilation of this report.
Two of the academic authors wrote the first 
draft of the manuscript, which was reviewed, 
modified, and approved in its final version by all 
the authors. Editorial assistance that did not 
involve writing was provided by Apothecom and 
funded by the sponsor. All the authors vouch for 
the accuracy and completeness of the data re-
ported and for the fidelity of the study to the 
protocol (available with the full text of this ar-
ticle at NEJM.org). 
RANDOMIZATION AND TREATMENT
From January 2013 through January 2014, we en-
rolled 495 patients at 135 sites in the United States, 
Canada, Australia, New Zealand, Europe, Russia, 
Turkey, and Israel. Patients were randomly assigned 
in a 1:1 ratio to receive vemurafenib orally (at a 
dose of 960 mg twice daily) together with either 
placebo (control group) or cobimetinib (at a dose 
of 60 mg once daily for 21 days, followed by 7 days 
off) (combination group). The study treatment con-
tinued until patients withdrew consent, unaccept-
able adverse effects arose, or disease progression 
occurred. Continuation of the study treatment or 
crossover after disease progression was not per-
mitted. Study patients were stratified according 
to American Joint Committee on Cancer stage and 
geographic region. To manage adverse events, we 
allowed modifications to the dose of both vemu-
rafenib and cobimetinib, with dose modifications 
for prespecified levels of toxic events (i.e., grade ≥2; 
see the study protocol).
STUDY END POINTS
The primary end point was progression-free sur-
vival as assessed by the investigator, according to 
RECIST criteria, version 1.1. The secondary end 
points included overall survival, rate of confirmed 
objective response according to RECIST criteria, 
version 1.1, duration of response, progression-free 
survival as assessed by an independent review fa-
cility, and safety (assessed according to the study 
treatment received). Tumor assessments were car-
ried out at baseline and every 8 weeks, and we 
performed a blinded, independent central review 
of tumor assessments.
STATISTICAL ANALYSIS
The prespecified number of progression events 
(206 events) was reached in May 2014, and the 
results reported here are based on data analyses 
from July 2014 (database locked on July 10, 2014). 
All the efficacy analyses were carried out in the 
intention-to-treat population. We estimated that 
206 progression events would provide the study 
with at least 95% power to detect a hazard ratio 
for death or progression of disease of 0.55, with 
an alpha level of 0.05 (an increase in the median 
progression-free survival, from 6 months for vem-
urafenib and placebo to 11 months for vemuraf-
enib plus cobimetinib). Progression-free survival 
was defined as the time between the date of ran-
domization and the date of the first documented 
event of disease progression or death, whichever 
occurred first according to the assessment of the 
site investigator.
We used the Kaplan–Meier method to estimate 
rates of progression-free and overall survival and 
used a stratified log-rank test for all the compari-
sons. Response rates and 95% confidence intervals 
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are reported for the two study groups. Differences 
in the response rate between the two treatment 
groups were tested with the use of a chi-square 
test with Schouten correction.17 We used the 
Kaplan–Meier method to calculate median and 
interquartile ranges to summarize the duration 
of response. Safety analyses included all the pa-
tients who had received at least one dose of a 
study drug.
The final analysis of overall survival will occur 
after 385 deaths are recorded, which we estimate 
will provide the study with 80% power to detect a 
hazard ratio for death of 0.75. Two interim analy-
ses have been planned. The first interim analysis 
was performed at the time of the final analysis of 
progression-free survival, and the second inter-
im analysis of overall survival will be triggered 
after 256 deaths have occurred. A Lan–DeMets 
implementation of an O’Brien–Fleming bound-
ary function was used in the analysis of overall 
survival.18
R ESULT S
PATIENTS
A total of 1049 patients were screened, and 495 
patients with BRAF V600–mutated metastatic 
melanoma were randomly assigned to receive vem-
u rafenib and cobimetinib (247 patients) or vem u-
rafenib and placebo (248) (Fig. S1 in the Supple-
mentary Appendix, available at NEJM.org). The 
most common reason for exclusion from the 
study was a negative test result for the BRAF V600 
mutation. The characteristics of the patients at 
baseline were generally well balanced between 
the two study groups (Table 1). Visceral metasta-
ses were present in 59% of the patients in the 
Table 1. Characteristics of the Patients.*
Characteristic
Vemurafenib  
and Placebo
(N = 248)
Vemurafenib  
and Cobimetinib
(N = 247)
Age — yr
Median 55 56
Range 25–85 23–88
Male sex — no. (%) 140 (56) 146 (59)
White race — no. (%)† 235 (95) 227 (92)
Geographic region — no. (%)
Australia, New Zealand, or Israel 38 (15) 40 (16)
Europe‡ 184 (74) 182 (74)
North America 26 (10) 25 (10)
ECOG performance-status score —  
no./total no. (%)§
0 164/244 (67) 184/243 (76)
1 80/244 (33) 58/243 (24)
2 0/244 1/243 (<1)
Metastatic status — no. (%)¶
Unresectable stage IIIC 13 (5) 21 (9)
M1a 40 (16) 40 (16)
M1b 42 (17) 40 (16)
M1c 153 (62) 146 (59)
Elevated LDH — no./total no. (%) 104/242 (43) 112/242 (46)
History of brain metastases — no. (%) 2 (1) 1 (<1)
BRAF-mutation genotype — no. (%)‖
V600E 174 (70) 170 (69)
V600K 32 (13) 24 (10)
Could not be evaluated 42 (17) 53 (21)
* There were no significant differences in baseline characteristics between the 
study groups. LDH denotes lactate dehydrogenase.
† Race was determined by the investigator.
‡ The data for patients from Russia and Turkey were included with those for 
Europe.
§ An Eastern Cooperative Oncology Group (ECOG) performance-status score of 
0 indicates that the patient is fully active and able to carry on all performance 
without restriction and a score of 1 that the patient is restricted in physically 
strenuous activity but ambulatory and able to carry out work of a light or sed-
entary nature. One patient randomly assigned to receive vemurafenib and co-
bimetinib had an ECOG performance-status score of 1 at randomization but 
had an ECOG performance-status score of 2 (indicating the patient is ambula-
tory and capable of all self-care but is unable to carry out any work activities 
and is out of bed more than 50% of waking hours) after randomization but 
before the first dose was received.
¶ The criteria of the American Joint Committee on Cancer for distant metastasis 
are as follows: M1a indicates metastases to skin, subcutaneous tissue, or dis-
tant lymph nodes; M1b metastases to lung; and M1c metastases to all other 
visceral sites or distant metastases to any site combined with an elevated se-
rum LDH level.
‖ After randomization, we characterized tumor DNA to identify specific V600 
mutations using next-generation sequencing. Cases that could not be evaluat-
ed were those in which either no tumor sample was provided or sequencing 
could not be performed on the tissue provided.
Figure 1 (facing page). Progression-free Survival in  
the Intention-to-Treat Population and Prespecified 
Subgroups.
Panel A shows Kaplan–Meier estimates of progres-
sion-free survival (as assessed by the site investiga-
tors) in the intention-to-treat population. The tick marks 
indicate censored data, and the dashed line 50% sur-
vival. Panel B shows hazard ratios and 95% confi-
dence intervals (error bars) for progression-free surviv-
al in prespecified subgroups of patients, according to 
various baseline characteristics. The data for patients 
from Russia and Turkey were included with those for 
Europe. The size of the blue boxes indicates the num-
ber of events, and the dashed line the hazard ratio for 
the risk of disease progression or death in the overall 
population. NR denotes not reached.
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Vemurafenib + cobimetinib
Vemurafenib + placebo
152
118
3
215
200
1
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Geographic region
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0
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0.01
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combination group and in 62% of those in the 
control group. At baseline, 46% and 43% of the 
patients, respectively, had an elevated lactate de-
hydrogenase level. The median follow-up of pa-
tients at the time of reporting was 7.3 months 
(range, 0.5 to 16.5).
EFFICACY
Progression-free Survival
The combination of vemurafenib and cobimetinib 
significantly prolonged progression-free survival 
according to investigator assessment in the inten-
tion-to-treat population: a median of 9.9 months 
(95% confidence interval [CI], 9.0 to not reached), 
as compared with 6.2 months (95% CI, 5.6 to 
7.4) in patients treated with vemurafenib and 
placebo. The hazard ratio for death or progres-
sion of disease was 0.51 (95% CI, 0.39 to 0.68; 
P<0.001) (Fig. 1A). The benefit for progression-
free survival was evident in all the prespecified 
patient subgroups (Fig. 1B) and according to 
analysis by independent radiology central re-
view (Table 2, and Fig. S2 in the Supplementary 
Appendix).
Table 2. Efficacy Summary.*
End Point
Vemurafenib 
and Placebo
(N = 248)
Vemurafenib 
 and Cobimetinib
(N = 247)
Progression-free survival
According to investigator assessment†
Median duration — mo (95% CI) 6.2 (5.6–7.4) 9.9 (9.0–NR)
Hazard ratio for death or disease progression (95% CI) Reference 0.51 (0.39–0.68)
P value Reference <0.001
According to assessment by independent review facility†
Median duration — mo (95% CI) 6.0 (5.6–7.5) 11.3 (8.5–NR)
Hazard ratio for death or disease progression (95% CI) Reference 0.60 (0.45–0.79)
P value Reference <0.001
Best response — no. (%)
Complete response 11 (4) 25 (10)
Partial response 100 (40) 142 (57)
Stable disease 105 (42) 49 (20)
Progressive disease 25 (10) 19 (8)
No complete response or progressive disease 1 (<1) 0
Could not be evaluated‡ 6 (2) 12 (5)
Complete or partial response
No. of patients 111 167
Percent of patients (95% CI) 45 (38–51) 68 (61–73)
P value Reference <0.001
Median duration of response — mo (95% CI) 7.3 (5.8–NR) NR (9.3–NR)
Overall survival at 9 mo — % (95% CI) 73 (65–80) 81 (75–87)
Overall survival†
Median duration — mo (95% CI) NR NR
Hazard ratio for death (95% CI) Reference 0.65 (0.42–1.00)
P value Reference 0.046
* NR denotes not reached.
† Patients were stratified according to geographic region and metastasis classification.
‡ Responses could not be evaluated for patients who withdrew consent, were withdrawn by the site investigator, died, or 
started new anticancer therapy before the first tumor assessment.
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Overall Survival
The interim analysis of overall survival in the 
intention-to-treat population showed that the rate 
of overall survival at 9 months for the combina-
tion of vemurafenib and cobimetinib was 81% 
(95% CI, 75 to 87), as compared with 73% (95% 
CI, 65 to 80) with vemurafenib and placebo (Ta-
ble 2 and Fig. 2). This assessment of overall sur-
vival was performed at the time of the final anal-
ysis of progression-free survival, and at this early 
time point, it had not crossed the prespecified 
hazard-ratio boundary for significance (observed 
hazard ratio for death, 0.65; 95% CI, 0.42 to 1.00; 
P = 0.046; boundary P<0.0000037). The absolute 
number of deaths was 34 in the combination 
group and 51 in the control group, and the me-
dian overall survival was not reached in either 
study group.
Response
The investigator-assessed response rate was sig-
nificantly higher in the combination group than 
in the control group (Table 2). Overall, 68% of 
patients in the combination group had an objec-
tive response, as compared with 45% in the con-
trol group (P<0.001) (Fig. S3 in the Supplemen-
tary Appendix). The rate of complete response 
was also significantly higher in the combination 
group than in the control group (10% vs. 4%). 
The majority of responses were seen by the time 
of the first tumor assessment at 8 weeks (Fig. S4 
in the Supplementary Appendix). The median du-
ration of response was 7.3 months in the control 
group, and the median was not reached in the 
combination group (Table 2). 
SAFETY
A total of 493 patients (>99%) received at least 
one dose of study drug and were included in the 
safety analysis. Adverse events that were reported 
in at least 20% of patients in either group are shown 
in Table 3. The combination of vemurafenib and 
cobimetinib was associated with a higher frequen-
cy of certain events than the single-agent therapy, 
including central serous retinopathy, gastrointes-
tinal events (diarrhea, nausea, or vomiting), pho-
tosensitivity, elevated aminotransferase levels, 
and an increased creatine kinase level; the major-
ity (>50%) of these individual events were grade 1 
or 2 (Table 3).
We observed equivalent rates of grade 3 events 
(49%) in the two study groups and substantially 
fewer grade 4 events (9% in the control group vs. 
13% in the combination group), with close to 
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Figure 2. Kaplan–Meier Estimates of Overall Survival in the Intention-to-Treat Population.
The tick marks indicate censored data, and the dashed line 50% survival.
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half of these in the experimental group being due 
to laboratory abnormalities (elevated aspartate 
aminotransferase, alanine aminotransferase, and 
creatine kinase levels) but without symptoms. An 
elevated creatine kinase level, a known class effect 
of MEK blockade, was the single most common 
grade 4 event (4%) seen with the combination 
therapy, although the majority of events related to 
creatine kinase (66%) were grade 1 or 2.
Some toxic events were observed at a lower 
frequency in the combination group than in the 
control group, including keratoacanthomas and 
cutaneous squamous-cell carcinoma, alopecia, 
and arthralgias. Rates of clinically significant 
cardiac events (QT-interval prolongation and de-
creased ejection fraction) were low and similar 
in the two groups, as was pyrexia, with only four 
patients with grade 3 events (all in the combina-
Table 3. Common Adverse Events.*
Adverse Event Vemurafenib and Placebo (N = 239) Vemurafenib and Cobimetinib (N = 254)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
number of patients (percent)
Any adverse event 21 (9) 70 (29) 117 (49) 22 (9) 19 (7) 66 (26) 125 (49) 34 (13)
Most common adverse events†
Diarrhea 51 (21) 16 (7) 0 0 99 (39) 29 (11) 16 (6) 0
Nausea 43 (18) 12 (5) 2 (1) 0 75 (30) 22 (9) 2 (1) 0
Vomiting 21 (9) 6 (3) 2 (1) 0 41 (16) 10 (4) 3 (1) 0
Rash 46 (19) 27 (11) 12 (5) 0 55 (22) 29 (11) 13 (5) 2 (1)
Photosensitivity reaction 25 (10) 12 (5) 0 0 48 (19) 18 (7) 6 (2) 0
Hyperkeratosis 49 (21) 14 (6) 5 (2) 0 23 (9) 3 (1) 0 0
Fatigue 42 (18) 24 (10) 7 (3) 0 48 (19) 24 (9) 9 (4) 0
Pyrexia 43 (18) 10 (4) 0 0 49 (19) 13 (5) 4 (2) 0
Arthralgia 53 (22) 31 (13) 12 (5) 0 54 (21) 23 (9) 6 (2) 0
Alopecia 55 (23) 14 (6) 1 (<1) 0 33 (13) 1 (<1) 1 (<1) 0
Increased alanine aminotrans-
ferase
17 (7) 11 (5) 14 (6) 1 (<1) 16 (6) 15 (6) 28 (11) 1 (<1)
Increased aspartate amino-
transferase
15 (6) 10 (4) 4 (2) 1 (<1) 17 (7) 18 (7) 21 (8) 0
Increased creatine kinase 6 (3) 1 (<1) 0 0 23 (9) 27 (11) 17 (7) 9 (4)
Selected adverse events
Cutaneous squamous-cell  
carcinoma
0 0 27 (11) 0 0 1 (<1) 6 (2) 0
Keratoacanthoma 1 (<1) 1 (<1) 18 (8) 0 0 0 2 (1) 0
Chorioretinopathy 1 (<1) 0 0 0 17 (7) 12 (5) 1 (<1) 0
Retinal detachment 0 0 0 0 9 (4) 6 (2) 5 (2) 1 (<1)
Decreased ejection fraction 0 4 (2) 3 (1) 0 2 (1) 14 (6) 3 (1) 0
QT-interval prolongation 8 (3) 2 (1) 3 (1) 0 6 (2) 2 (1) 1 (<1) 0
* The safety population was analyzed according to the study treatment received. Eight patients assigned to the control group received investi-
gational cobimetinib as a result of dispensing errors. Two patients (one in each study group) did not receive the assigned study drug and 
were therefore excluded from the safety analysis. Multiple occurrences of a specific adverse event for a patient were counted once at the 
highest grade of the occurrence, according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 
For example, if a patient had two episodes of a specific toxic event, one grade 3 and one grade 4, the patient was counted only once, in the 
grade 4 column. Similarly, in the “Any adverse events” row, if a patient had, for example, three separate events of grade 1, 3, and 4, the pa-
tient was counted only once, in the grade 4 column.
† The most common adverse events were those that occurred in at least 20% of the patients in either study group.
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tion group). Overall, six deaths were attributed 
to adverse events in the combination group and 
three deaths in the control group (Table S1 in the 
Supplementary Appendix). Despite differences be-
tween the two groups in the type and frequency 
of adverse events, the incidence of toxic events 
leading to the withdrawal from treatment was 
similar (12% in the control group and 13% in 
the combination group). At the time of the data 
cutoff, a total of 85 patients had died, primar-
ily as a result of disease progression (96% of the 
deaths in the control group and 85% of those 
in the combination group were due to pro-
gression).
DISCUSSION
This phase 3 study showed an improvement in 
the response rate and in progression-free surviv-
al when cobimetinib was added to vemurafenib. 
Together with the results of a phase 3 trial com-
paring dabrafenib plus trametinib with dabrafenib 
alone,19 these findings provide clear evidence of 
the benefit of combined MEK and BRAF inhibi-
tion. The data combining BRAF and MEK inhibi-
tor–targeted therapies need to be put in context 
with the rapidly evolving melanoma-treatment 
landscape — namely, the development of immu-
notherapies that are based on checkpoint block-
ade with ipilimumab or anti–programmed death 1 
antibodies. Evidence suggests that these agents 
can lead to durable tumor responses in patients 
with metastatic melanoma, albeit with lower re-
sponse rates than have been observed with BRAF 
and MEK inhibition.20-23
The primary end point of the hazard ratio for 
the risk of progression or death that we report 
for vemurafenib plus cobimetinib, as compared 
with vemurafenib alone, is significant. The data 
from the prespecified interim analysis of overall 
survival we report here are immature, reflecting 
analysis at the time of the planned analysis of 
progression-free survival, and they do not cross 
the boundary prespecified in the statistical analy-
sis plan. Nevertheless, these early data are encour-
aging, although mature data are needed before 
definitive conclusions can be drawn. The consis-
tency between both primary and secondary end 
points and subgroups is a strength of the current 
study, as was the performance of the control 
group, which was broadly consistent with prior 
randomized trials of BRAF inhibitors in both the 
response rate and median progression-free sur-
vival.3,4 It is possible that the intermittent dosing 
regimen of cobimetinib, resulting from the defi-
nition of the maximum tolerated dose in phase 1 
testing,15 might have an effect on the outcomes of 
the combination with vemurafenib: preclinical 
data suggest that the intermittent blockade of on-
cogenic BRAF signaling might delay the develop-
ment of acquired resistance.24
The majority of common toxic events seen 
with the combination of vemurafenib and cobi-
metinib were of grade 1 or 2 (Table 3). With rela-
tively long-term treatment with vemurafenib and 
cobimetinib, it is important to distinguish side 
effects of the combination therapy (e.g., nausea, 
vomiting, and diarrhea) that can be managed with 
appropriate supportive interventions. In this study, 
several MEK inhibitor–specific toxic events were 
observed. An asymptomatic elevated creatine ki-
nase level is a known class effect of MEK inhibi-
tion and was observed in 30% of patients with 
exposure to vemurafenib and cobimetinib in our 
study, the majority of events being grade 1 or 2 and 
rapidly reversible. MEK inhibitors are also asso-
ciated with ocular conditions resembling central 
serous retinopathy,25,26 recently referred to in the 
literature as transient drug-induced retinopathy.26 
Consistent with previous reports, most cases (86%) 
of retinopathy in our study were grade 1 (clini-
cally asymptomatic) or 2 (moderate decrease in 
visual acuity), were found to be reversible at 
subsequent ophthalmic examinations in the ma-
jority of cases without any treatment, or were 
managed with dose reduction or withdrawal of 
cobimetinib.
In conclusion, the combination of vemu-
rafenib and cobimetinib, as compared with 
vemurafenib alone, resulted in an improvement 
in progression-free survival and objective re-
sponses, with early evidence of improved overall 
survival and a somewhat increased toxicity pro-
file, among patients with advanced BRAF-mutated 
melanoma.
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